Trial Profile

A Phase 2, randomized, placebo-controlled study of NED-260 in mild-to-moderate COVID-19 patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NED-260 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Nov 2020 New trial record
06 Oct 2020 According to a NED Biosystems media release, Dr. Michael Mansour, as a medical advisor will direct company's clinical trial initiative for NED-260 to establish the treatment's safety and efficacy for COVID-19 patients.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com